Myriad Genetics (MYGN) Competitors $7.24 -0.44 (-5.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.36 +0.13 (+1.73%) As of 09/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MYGN vs. BCRX, MNKD, CLDX, INVA, NVAX, DVAX, OPK, GERN, ZBIO, and RIGLShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Its Competitors BioCryst Pharmaceuticals MannKind Celldex Therapeutics Innoviva Novavax Dynavax Technologies OPKO Health Geron Zenas BioPharma Rigel Pharmaceuticals BioCryst Pharmaceuticals (NASDAQ:BCRX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Is BCRX or MYGN more profitable? BioCryst Pharmaceuticals has a net margin of -6.41% compared to Myriad Genetics' net margin of -47.45%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-6.41% N/A -1.78% Myriad Genetics -47.45%-5.17%-3.44% Which has more volatility and risk, BCRX or MYGN? BioCryst Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Do institutionals and insiders hold more shares of BCRX or MYGN? 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, BCRX or MYGN? BioCryst Pharmaceuticals has higher earnings, but lower revenue than Myriad Genetics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$450.71M3.68-$88.88M-$0.18-43.94Myriad Genetics$832.90M0.81-$127.30M-$4.28-1.69 Does the media refer more to BCRX or MYGN? In the previous week, Myriad Genetics had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 6 mentions for Myriad Genetics and 5 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.51 beat Myriad Genetics' score of 1.17 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Myriad Genetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BCRX or MYGN? BioCryst Pharmaceuticals presently has a consensus price target of $16.70, suggesting a potential upside of 111.13%. Myriad Genetics has a consensus price target of $12.45, suggesting a potential upside of 72.02%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Myriad Genetics 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21 SummaryBioCryst Pharmaceuticals beats Myriad Genetics on 11 of the 16 factors compared between the two stocks. Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$673.65M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-1.6921.5775.4626.02Price / Sales0.81254.90464.4091.13Price / Cash7.2544.4425.8129.91Price / Book0.949.6112.166.25Net Income-$127.30M-$53.29M$3.29B$270.76M7 Day Performance4.78%0.57%0.73%2.54%1 Month Performance26.80%4.56%4.41%5.73%1 Year Performance-73.76%10.44%62.61%25.85% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics3.706 of 5 stars$7.24-5.7%$12.45+72.0%-73.8%$673.65M$832.90M-1.692,700Positive NewsBCRXBioCryst Pharmaceuticals4.2534 of 5 stars$8.19-1.0%$16.70+103.9%-0.1%$1.74B$450.71M-45.50530Positive NewsMNKDMannKind4.4148 of 5 stars$5.57+0.5%$10.71+92.4%-11.2%$1.70B$285.50M50.64400Positive NewsShort Interest ↓CLDXCelldex Therapeutics2.3946 of 5 stars$23.40+2.3%$46.67+99.4%-44.6%$1.52B$7.02M-7.77150Positive NewsINVAInnoviva4.85 of 5 stars$20.46-0.1%$42.75+108.9%-2.2%$1.29B$358.71M66.00100Positive NewsAnalyst DowngradeShort Interest ↓NVAXNovavax4.4832 of 5 stars$7.73-2.2%$14.29+84.8%-41.4%$1.28B$1.08B3.391,990Positive NewsDVAXDynavax Technologies4.4614 of 5 stars$9.70-3.6%$24.33+150.9%-15.8%$1.18B$316.27M-21.09350Positive NewsOPKOPKO Health4.3991 of 5 stars$1.42+5.2%$2.75+93.7%-10.8%$1.07B$713.10M-5.682,997GERNGeron3.1242 of 5 stars$1.37-2.1%$4.19+205.7%-71.8%$893.22M$76.99M-10.5470Positive NewsZBIOZenas BioPharma1.192 of 5 stars$21.51+4.9%$36.67+70.5%N/A$863.68M$5M0.00N/AHigh Trading VolumeRIGLRigel Pharmaceuticals1.9142 of 5 stars$40.87-1.1%$38.20-6.5%+177.1%$741.53M$179.28M7.55160Positive News Related Companies and Tools Related Companies BCRX Alternatives MNKD Alternatives CLDX Alternatives INVA Alternatives NVAX Alternatives DVAX Alternatives OPK Alternatives GERN Alternatives ZBIO Alternatives RIGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYGN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYGN Stock Alerts